Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358419 | 1.00 | MEN1 (0.38) | MEN1KMT2ACES2HDAC1HDAC2 | |
| SCHEMBL5246328 | 0.96 | CES2 (0.40) | MEN1KMT2ACES2HDAC1HDAC2 | |
| SCHEMBL5245265 | 0.89 | CES2 (0.46) | MEN1KMT2ACES2HDAC1HDAC2 | |
| SCHEMBL27297810 | 0.82 | CES2 (0.41) | CES2HDAC1HDAC2EPHX2CYP2C19 | |
| SCHEMBL5251554 | 0.81 | ALDH1A1 (0.50) | MEN1KMT2AHDAC1HDAC2PMP22 | |
| SCHEMBL5346360 | 0.80 | BLM (0.33) | CES2BLMPMP22HSD17B10TSHR | |
| SCHEMBL5356441 | 0.80 | BLM (0.33) | CES2BLMPMP22HSD17B10TSHR | |
| SCHEMBL23405393 | 0.77 | CES2 (0.46) | MEN1KMT2ACES2EPHX2CYP2C19 | |
| SCHEMBL20534923 | 0.77 | EPHX2 (0.42) | MEN1KMT2ACES2HDAC1HDAC2 | |
| SCHEMBL22922080 | 0.76 | CES2 (0.44) | CES2HDAC1HDAC2EPHX2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217409-B2 | Alkanoic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | claimed |
| US-20040067202-A1 | Novel alkanoic acid derivaties | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | US | claimed |
| EP-1318973-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024623-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | claimed |
| US-7217409-B2 | Alkanoic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040067202-A1 | Novel alkanoic acid derivaties | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | US | disclosed |
| EP-1318973-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024623-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067202-A1 | Novel alkanoic acid derivaties | ALK, FFAR1, FFAR3 | MEN1 2802/4885KMT2A 3498/4885CES2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.